RIO DE JANEIRO, BRAZIL - Moderna said Wednesday, February 24th, that it has completed the initial batch of doses of a new covid-19 vaccine designed to better protect against the new South African variant, which has shown some resistance to the company's original immunizer.
The company said it has sent the new vaccines to the National Institutes of Health (NIH) to conduct the first human trial, which could begin within weeks.
The new vaccine is designed to better match the virus variant first detected in South Africa, but which has since spread to other areas. Moderna may be the . . .